- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1,933)
21 result(s) found for: RIS.
Displaying page 1 of 2.
EudraCT Number: 2007-001541-18 | Sponsor Protocol Number: T3RIS22007 | Start Date*: 2007-10-08 | |||||||||||
Sponsor Name:Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine | |||||||||||||
Full Title: Triiodothyronine as an adjunct in treatment of acute schizophrenia | |||||||||||||
Medical condition: Acute Schizoprenia episode | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000736-10 | Sponsor Protocol Number: BCG-RIS-01 | Start Date*: 2019-01-24 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS | |||||||||||||
Full Title: “Bacille Calmette-Guérin (BCG) vaccine In Radiologically Isolated Syndrome (Ris)” | |||||||||||||
Medical condition: Radiologically Isolated Syndrome (Ris) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022181-28 | Sponsor Protocol Number: 13639A | Start Date*: 2011-02-07 | ||||||||||||||||||||||||||
Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||||||||||||
Full Title: A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia | ||||||||||||||||||||||||||||
Medical condition: Schizophrenia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Completed) EE (Completed) CZ (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-002979-33 | Sponsor Protocol Number: RIS-USA-234 | Start Date*: 2006-01-19 |
Sponsor Name:Janssen-Cilag International N.V. | ||
Full Title: Estudio de la eficacia y seguridad de risperidona en el tratamiento de adolescentes con esquizofrenia: Estudio abierto de seis meses. | ||
Medical condition: SCHIZOPHRENIA/ Adolescents | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003233-34 | Sponsor Protocol Number: 11048 | Start Date*: 2012-01-19 |
Sponsor Name:University of Nottingham | ||
Full Title: The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients – a pilot study | ||
Medical condition: Anaemia following hip fracture | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001731-39 | Sponsor Protocol Number: STRIM002-(205813) | Start Date*: 2017-10-12 | |||||||||||
Sponsor Name:Orchard Therapeutics (Europe) Ltd | |||||||||||||
Full Title: Methodology study to investigate the utility of retroviral insertion site analysis in samples from subjects treated with Strimvelis™ gene therapy | |||||||||||||
Medical condition: Adenosine deaminase (ADA) deficiency severe combined immunodeficiency | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004621-25 | Sponsor Protocol Number: RIS-SCH-4043 | Start Date*: 2006-01-30 | |||||||||||
Sponsor Name:Janssen-Cilag Medical Affairs EMEA | |||||||||||||
Full Title: Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta? | |||||||||||||
Medical condition: Schizophrenia, schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000830-35 | Sponsor Protocol Number: RIS-SCH-3007 | Start Date*: 2004-07-23 | |||||||||||
Sponsor Name:JANSSEN-CILAG | |||||||||||||
Full Title: Maintenance of the clinical response with long-acting injectable Risperidone in patients with Schizophrenia or schizoaffective disorders | |||||||||||||
Medical condition: Schizophrenia or schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000623-25 | Sponsor Protocol Number: 32492 | Start Date*: 2008-11-10 | ||||||||||||||||
Sponsor Name:University of Nottingham | ||||||||||||||||||
Full Title: Ondansetron for the treatment of IBS with diarrhoea (IBS-D): Identifying the “responder” | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome with Diarrhoea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001221-16 | Sponsor Protocol Number: RISSCH3024 | Start Date*: 2015-03-31 | |||||||||||
Sponsor Name:Janssen Cilag N.V./S.A | |||||||||||||
Full Title: A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002304-41 | Sponsor Protocol Number: RIS-SCH-4045 | Start Date*: 2005-09-23 |
Sponsor Name:Janssen-Cilag EMEA Medical Affairs | ||
Full Title: Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia or schizoaffective disorder after an acute episode | ||
Medical condition: Schizophrenia or schizoaffective disorder. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) FI (Completed) GB (Completed) SI (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001490-15 | Sponsor Protocol Number: RIS-BMN-3001 | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V | |||||||||||||
Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the... | |||||||||||||
Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001320-31 | Sponsor Protocol Number: RIS-AUT-JPN-01 | Start Date*: 2015-03-27 | |||||||||||
Sponsor Name:Janssen Pharmaceutical K.K | |||||||||||||
Full Title: A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents with Irritability Associa... | |||||||||||||
Medical condition: Autistic disorder in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001513-35 | Sponsor Protocol Number: | Start Date*: 2016-08-23 | ||||||||||||||||
Sponsor Name:NHS Blood and Transplant. [...] | ||||||||||||||||||
Full Title: TREATT: TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematologic... | ||||||||||||||||||
Medical condition: Bleeding secondary to thrombocytopaenia associated to haematological malignancies. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004969-27 | Sponsor Protocol Number: 69HCL17_0028 | Start Date*: 2018-05-28 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: A multicenter randomized open-label trial comparing the efficacy and safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis CIRIS: Cyclophosphamide vs. Infli... | |||||||||||||
Medical condition: anterior idiopathic scleritis or anterior and posterior idiopathic scleritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012003-26 | Sponsor Protocol Number: RIS-NAP-4022 | Start Date*: 2010-04-13 | |||||||||||||||||||||
Sponsor Name:Janssen-Cilag International, NV | |||||||||||||||||||||||
Full Title: Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs | |||||||||||||||||||||||
Medical condition: Long-term safety data in children and adolescents will be collected from a population of patients with a diagnosis of schizophrenia, bipolar mania, autistic disorder or conduct and other disruptive... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000780-24 | Sponsor Protocol Number: MOR202C103 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | |||||||||||||
Medical condition: Primary (anti-PLA2R antibody positive) Membranous Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011343-39 | Sponsor Protocol Number: RIS-SCH-4226 | Start Date*: 2009-06-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag AB | |||||||||||||||||||||||||||||||||
Full Title: Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders | |||||||||||||||||||||||||||||||||
Medical condition: Schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder patients demanding long term antipsychotic treatment | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000870-29 | Sponsor Protocol Number: RISSCH3001 | Start Date*: 2004-11-04 |
Sponsor Name:Janssen-Cilag Medical Affairs EMEA | ||
Full Title: CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness | ||
Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) ES (Completed) AT (Completed) SE (Completed) CZ (Completed) LV (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000522-18 | Sponsor Protocol Number: 2016-01 | Start Date*: Information not available in EudraCT |
Sponsor Name:PIBDNet | ||
Full Title: Risk stratified randomized controlled trial in paediatric Crohn’s Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive... | ||
Medical condition: Crohn’s disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Ongoing) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Ongoing) CZ (Completed) IT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
